
Lundbeck has launched Sycrest in the UK for the treatment of acute attacks of bipolar I disorder. Sycrest (asenapine) is …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

